ASCO 2015 - Prostate Cancer

Viewing 1-11 of 11 articles

ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights

ASCO - Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE - Session Highlights

ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights

ASCO - ARAMIS: Novel oral androgen receptor inhibitor ODM-201 enters phase 3 study in nmCRPC - Session Highlights

#ASCO15 - ODM-201 demonstrates high anticancer activity and favorable tolerability in the ARADES phase I/II trial in mCRPC - Session Highlights

ASCO 2015 - Long-term consequences of intermittent and continuous androgen deprivation in men with metastatic prostate cancer - Session Highlights

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Early treatment with docetaxel chemotherapy - Session Highlights

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Late treatment with docetaxel chemotherapy - Session Highlights

ASCO - Bottom line: Timing of treatment with docetaxel for men with advanced prostate cancer - Session Highlights

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.